Connect with us
  • Elysium


Are star-shaped brain cells involved in stuttering?



"Our data suggests astrocytes in the striatum may be playing an important role in the development of stuttering."

Star-shaped brain cells could play an important role in stuttering, new research has revealed.

The cells, called astrocytes, are actively involved in brain function, and a new study has revealed their role in stuttering.

Stuttering, a childhood onset fluency disorder that leads to speech impairment, is associated with high levels of the neurotransmitter dopamine.

“Our study suggests that treatment with the medication risperidone leads to increased activity of the striatum in persons who stutter,” said Dr. Gerald A. Maguire, professor and chair of the Department of Psychiatry and Neuroscience at UCR School of Medicine, who led the study.

“The mechanism of risperidone’s action in stuttering, in part, appears to involve increased metabolism – or activity – of astrocytes in the striatum.”

The striatum is a key component of the basal ganglia, a group of nuclei best known for facilitating voluntary movement. Present in the forebrain, the striatum contains neuronal activity related to cognition, reward, and coordinated movements.

Risperidone works by blocking the receptors in the brain that dopamine acts on, thus preventing excessive dopamine activity.

The medication is available by prescription under a physician’s order almost anywhere in the world. In existence for nearly 30 years, it is generally prescribed for schizophrenia and bipolar disorder.

In this study, a collaboration between Dr Maguire and Shahriar SheikhBahaei, an independent research scholar at the National Institutes of Health’s National Institute of Neurological Disorders and Stroke, evidence has been found that that astrocytes in the striatum may be crucially involved in how risperidone is able to reduce stuttering.

“We do not know the exact mechanism for how risperidone activates astrocytes in the striatum,” said co-author SheikhBahaei.

“What we know is that it activates astrocytes. The astrocytes then release a signalling molecule that affects neurons in the striatum by blocking their dopamine receptors.

“In our future work, we would like to find this signalling molecule and better understand the exact role astrocytes play in stuttering, which, in turn, could help us design drugs that target astrocytes.”

Maguire and his team conducted a randomised, double-blinded placebo-controlled clinical trial with 10 adult subjects to observe risperidone’s effects on brain metabolism.

At the start of the study and after six weeks of taking risperidone (0.5-2.0 mg/day) or a placebo pill, the 10 participants were assigned to a solo reading aloud task.

The participants then each underwent a positron emission tomography, or PET, scan.

Five subjects got risperidone while the other five got a placebo. Those in the risperidone treatment group were found to show higher glucose uptake –  or higher metabolism – in specific regions of the brain according to scans taken after active treatment.

“Naturally, and abnormally, glucose uptake is low in stuttering – a feature common to many neurodevelopmental conditions,” says Dr Maguire, who also is a person who stutters.

“But risperidone seems to compensate for the deficit by increasing the metabolism, specifically, in the left striatum. More research is needed to understand this better.

“Neuroimaging techniques we used to visualise changes in the brains of those who stutter can provide valuable insights into the pathophysiology of the disorder and guide the development of future interventions.”

Next, the researchers will aim to further understand what causes stuttering, what the different types of stuttering are, what may be their etiologies, allowing them to develop targeted personalised treatments for those who stutter.

“The general goal of our research collaboration is to combine basic research in my lab with Dr Maguire’s clinical studies,” SheikhBahaei said.

“Our data, which suggests astrocytes in the striatum may be playing an important role in the development of stuttering, helps unify some of the findings the scientific literature has seen recently on astrocytes and could help connect the dots.”


New company launched to drive forward Parkinson’s research



Up to £800,000 will be invested over the next two years

Charity Parkinson’s UK is to launch a new company dedicated to driving forward research into Parkinson’s disease.

Vivifi Biotech has been created to lead and plan preparations for a new trial into the role of the restorative protein glial cell-derived neurotrophic factor (GDNF) in Parkinson’s.

Launched through the charity’s drug development arm, Parkinson’s Virtual Biotech, up to £800,000 will be invested over the next two years as efforts continue to find a life-changing new treatment for people living with the disease.

Plans for a new trial build on the initial groundbreaking clinical investigations in GDNF, the results of which proved inconclusive but did show some signs that the treatment may have started to regenerate participants’ dopamine-producing brain cells.

“The unwavering passion and determination of the GDNF participant group has ensured that the potential of GDNF, and the role of patients in research, has never been forgotten,” says Paul Jackson Clark, director of engagement at Parkinson’s UK.

“They’ve tirelessly campaigned, fundraised and shared their experience with us, enabling us all to get to this monumental point.

“We now have the chance to see if we can find a life-changing new treatment that people with Parkinson’s desperately need. There are still plenty of obstacles but this announcement gives us the opportunity to move things forward together.”

Parkinson’s UK was the major funder of the initial trial, which investigated whether boosting levels of GDNF could slow, stop or reverse the progression of Parkinson’s.

Tom Phipps was a participant in the GDNF trial.

“My outcome was as positive as I could have wished for, I feel the trial brought me some time and has delayed the progress of my condition,” he says.

“The trial participants have always believed in GDNF’s potential,” said Parkinson’s UK in their announcement.

“So have we and the other organisations involved in the trial.

“Some participants tell us they’re still experiencing the benefits, years on from undergoing this experimental therapy. We’ve been working with them since the end of the trial.

“Together, we want to make sure we’ve explored every option.”

Continue Reading

Community rehab

Music group launched to support BAME community



Leicester Musical Memory Box is launching its online music project Geet Sangeet

A music group established to support people living with dementia, memory loss and brain injury has received funding to launch an online project for the South Asian and BAME community.

Leicester Musical Memory Box (LMMBox) was founded in July 2018, and since that time has grown from one group in the city to six, providing interactive music sessions for people of all ages and backgrounds, including a group specific to the South Asian community.

The group – which has two staff members who are fluent in Gujarati, Hindi, Punjabi and Urdu – aims to provide the local community with a supportive network and a safe space to explore the unique challenges that a brain injury may bring to individuals, as well as their families and carers.

The new online music project is named ‘Geet Sangeet’ – translated as ‘Songs Sung Together’ – and will incorporate music and cultural references specific to the South Asian community, led by group leader Beena Masand from LMMBox.

Each session will begin with gentle exercises to warm up the body and brain, followed by singing and discussion about various music, songs, and media.

Attendees will also receive their own ‘musical memory box’ in a bag to help increase the interactivity of the sessions.

The project has received funding from the new Local Connections Fund, and is in collaboration with Headway Leicester.

Music has proven benefits for people with memory problems or a brain injury, including enabling people to connect with past experience and enabling freedom of expression, confidence and independence.

Attendance at the groups also helps to improve mood and reduce feelings of social isolation.

“We know we are providing a vital service to our members and receive enquiries regularly,” says Kyle Newman, group leader and co-director of LMMBox.

“In spite of the lockdown, we are thrilled to be able to once again provide a culturally specific group for the South Asian community.

“We also know that the group leader needs to come from that community and have the music and cultural knowledge to be able to engage participants effectively.”

“We are delighted to collaborate with LMMBox and reach out to more people across Leicester who have been affected by brain injury,” adds Mary Goulty, service manager at Headway Leicester.

“There is a clear need for a support service within the BAME community and that’s why we launched our BAME group last year, which is providing a vital lifeline to brain injury survivors we support and their families.”

To contact LMMBox, visit

For support with brain injury in the Leicester community, visit

Continue Reading


Art Therapy offers an emotional outlet for those living with a Traumatic Brain Injury (TBI)



Masks not only allow us to hide our true feelings but to also express them without fear of judgement.

Being able to ‘hide’ one’s true self, may be a way, for others, to truly ‘show’ themselves.

For this reason, Chroma therapists began delivering Art Therapy sessions online to those living with a Traumatic Brain Injury (TBI) in an attempt to help them express their emotions in a creative, non-threatening way.

A TBI can have devastating effects upon a person’s mental health, as well as physical, with emotional issues caused by significant, sudden changes in appearance and abilities.

Studies have found Art Therapy to be effective in helping TBI patients with emotional expression, socialisation, emotional adaptation to mental and physical disabilities, and communication in a creative and non-threatening way.1

Self-expression is fundamental in processing the effects of a TBI. Take a look at the image below.

On the left is the base mask. During the process of art therapy, across a number of sessions, the participant talks, reflects and begins to create ideas or metaphors which then get placed onto the base mask. Often this depicts the face he presents to the outside world, in contrast with the dual parts of to his inner personality including a bright peaceful side and a dark, tumultuous side.

Based on the sessions, Chroma therapists are better able to gauge the patient’s feelings, discuss the final piece and help the patient begin to process their emotions.

In effect, art therapy offers a creative gateway to communication and used in this way, tries to enable the participant to externalise their inner thoughts and feelings.

As a therapy, it has been shown to help reduce feelings of stress, promote creativity and imagination as well as increase self-expression, confidence and communication.

Chroma began delivering these sessions as a way to allow clients to reveal thoughts and feelings about themselves which they may find hard to express, or may not even be aware of, and which may be being expressed through more difficult behaviours.

They also create an opportunity for greater communication, allowing therapists to gain a deeper understanding of the client’s thoughts, anxieties and feelings.

Being able to express themselves creatively helps the client reveal their true feelings, which in itself can be cathartic – a relief to release their emotions, in a personal, safe space.

Chroma continues to deliver these sessions online to help reach as many TBI sufferers across the UK as possible in an attempt to help them begin to process their emotions concerning the effects the TBI had upon them, with the outlook to help improve their mental wellbeing which in turn will help promote a positive outlook to life and rehabilitation outcomes.

Continue Reading


Get the NR Times update